DeepMed Research

The Gynecologic Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1970-01-01

Employees: 11

Market Cap: -

Website: http://www.gog.org

Clinical Trials

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

First Posted Date: 2004-05-21

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 62

Registration Number: NCT00002813

Locations: 🇺🇸
CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

and more 6 locations

Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer

Phase 3

Completed

Conditions: Ovarian Cancer

First Posted Date: 2004-05-05

Last Posted Date: 2013-07-09

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 470

Registration Number: NCT00002568

Locations: 🇺🇸
Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

and more 52 locations

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Phase 2

Terminated

Conditions: Ovarian Cancer

First Posted Date: 2004-04-23

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00003386

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States

and more 57 locations

Chemotherapy in Treating Patients With Sarcoma of the Uterus

Phase 2

Completed

Conditions: Endometrial Cancer
Sarcoma

First Posted Date: 2004-04-19

Last Posted Date: 2013-06-10

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00005643

Locations: 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Tufts University School of Medicine, Boston, Massachusetts, United States
🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

and more 46 locations

Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus

Phase 2

Terminated

Conditions: Sarcoma

First Posted Date: 2004-04-09

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00003316

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States

and more 37 locations

Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia

Phase 2

Completed

Conditions: Cervical Carcinoma
Cervical Intraepithelial Neoplasia Grade 2/3
Stage 0 Cervical Cancer

Interventions: Drug: Celecoxib
Other: Laboratory Biomarker Analysis
Other: Placebo

First Posted Date: 2004-04-08

Last Posted Date: 2017-09-15

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 130

Registration Number: NCT00081263

Locations: 🇺🇸
Elkhart Clinic, Elkhart, Indiana, United States
🇺🇸
Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 40 locations

Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus

Phase 2

Terminated

Conditions: Sarcoma

First Posted Date: 2004-04-07

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00003156

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Tufts University School of Medicine, Boston, Massachusetts, United States

and more 43 locations

Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

First Posted Date: 2004-03-31

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00005031

Locations: 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 37 locations

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-03-31

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 24

Registration Number: NCT00003967

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

and more 3 locations

Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer

Phase 3

Completed

Conditions: Cervical Cancer

First Posted Date: 2004-03-26

Last Posted Date: 2013-07-09

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00002536

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 38 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy